Example: stock market
Electronic registration process - European …
Electronic registration process – EudraVigilance registration phases I, II and III EMA/101243/2016 Page 3/8 Step 3: Select transmission mode
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Related documents
ICH and EU regulatory framework and the role of …
www.ich.orgAlberto Ganan Jimenez, PhD –Quality of Medicines, European Medicines Agency (EMA) An agency of the European Union ICH and EU regulatory framework and the role of the European Medicines Agency (EMA)
The new Clinical Trial Regulation and corresponding …
dgra.deThe new portal and database have to be set up as completely new IT systems by the European Medicines Agency (EMA). These systems will be used to collect data about planned and
European Medicines Agency
www.ema.europa.euEuropean Medicines Agency 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 85 75 Fax (44-20) 75 23 70 40 E-mail: mail@emea.eu.int http://www.emea.eu.int
DEVELOPING A CULTURE OF …
www.pugatch-consilium.comDeveloping a Culture of Pharmacovigilance 3 LIST OF ABBREVIATIONS 4 EXECUTIVE SUMMARY 7 INTRODUCTION 11 1 THE IMPORTANCE OF MONITORING THE SAFETY OF MEDICINES 14 1.1 The biopharmaceutical R&D process 14
MEDICINES CONTROL COUNCIL - mccza.com
www.mccza.comRegistration of Medicines eCTD Submission in South Africa . 2.23_Submission_in_eCTD_format_Sept16_v2.1 Page April 2017. 1 of 26. MEDICINES CONTROL COUNCIL
DRUG REGISTRATION GUIDANCE DOCUMENT (DRGD)
npra.moh.gov.mydrug registration guidance document (drgd) drug registration guidance document (drgd) national pharmaceutical regulatory division ministry of health, malaysia
MULTISOURCE (GENERIC) PHARMACEUTICAL …
www.who.intWorking document QAS/14.583/Rev.1 July 2014 Document for comment 1 2 3 MULTISOURCE (GENERIC) PHARMACEUTICAL 4 PRODUCTS: GUIDELINES ON REGISTRATION 5 REQUIREMENTS TO ESTABLISH
From access to adherence - World Health …
www.who.intFrom access to adherence: the challenges of antiretroviral treatment Studies from Botswana, Tanzania and Uganda 2006 Anita Hardon University of Amsterdam